Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

Open access

Abstract

Immunotherapy with PD-1 checkpoint blockade is effective in only a minority of patients with cancer, suggesting that additional treatment strategies are needed. Here we use a pooled in vivo genetic screening approach using CRISPR-Cas9 genome editing in transplantable tumours in mice treated with immunotherapy to discover previously undescribed immunotherapy targets. We tested 2,368 genes expressed by melanoma cells to identify those that synergize with or cause resistance to checkpoint blockade. We recovered the known immune evasion molecules PD-L1 and CD47, and confirmed that defects in interferon-γ signalling caused resistance to immunotherapy. Tumours were sensitized to immunotherapy by deletion of genes involved in several diverse pathways, including NF-κB signalling, antigen presentation and the unfolded protein response. In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon-γ-mediated effects on antigen presentation and growth suppression. In vivo genetic screens in tumour models can identify new immunotherapy targets in unanticipated pathways.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature23270

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 1,147

Metadata

Authors
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., Weiss, S. A., Lo, J., Fisher, D. E., Miao, D., Van Allen, E., Root, D. E., Sharpe, A. H., Doench, J. G., & Haining, W. N.
Affiliations
  • Broad Institute (US)
  • Harvard University (US)
  • Dana-Farber Cancer Institute (US)
  • Boston Children's Hospital (US)
Corresponding author
Haining, W. Nicholas
Venue
Nature
Published
2017-07
Volume
547
Issue
7664
Pages
413-418
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2736476343
Cited by
1,147
References
36
Citations by year
2026: 96 · 2025: 123 · 2024: 133 · 2023: 144 · 2022: 145 · 2021: 136 · 2020: 136 · 2019: 115 · 2018: 98 · 2017: 17
FWCI
44.61
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • Broad Institute
  • National Cancer Institute (T32CA207021)
  • National Institute of General Medical Sciences (T32GM007753)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
PTPN2, protein tyrosine phosphatase, cancer immunotherapy, anti-PD-1 therapy, interferon-gamma signaling, antigen presentation, melanoma, immunotherapy resistance, NF-κB signaling, unfolded protein response, PD-L1, CD47, B16 melanoma
MeSH terms
Gene Editing, Loss of Function Mutation, Animals, Humans, Immunotherapy, Interferons, Melanoma, Experimental, T-Lymphocytes, NF-kappa B, Antigen Presentation, Tumor Escape, Xenograft Model Antitumor Assays, Genomics, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 2, Unfolded Protein Response, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. https://app.cochat.ai/papers/10.1038/nature23270
The paper
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., Weiss, S. A., Lo, J., Fisher, D. E., Miao, D., Van Allen, E., Root, D. E., Sharpe, A. H., Doench, J. G., & Haining, W. N. (2017). In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. https://doi.org/10.1038/nature23270

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.